Update on advanced basal cell carcinoma diagnosis and treatment Despite increased insight on skin cancer risk factors, the incidence continues to rise worldwide. This review article summarizes new treatment options available, which help to redefine and expand the diagnosis of advanced BCC and allow dermatologists to offer more effective therapy to a broader population. Clinical acumen key for identifying pediatric melanoma Experts discuss diagnosis and management of pediatric melanoma, including the latest developments in genetic tools and indications for sentinel lymph node biopsy. Staying current with therapeutic advances and expert insights This month we offer new insights and data to aid diagnosis and treatment of difficult conditions, as well as practical approaches to optimize outcomes. CeraVe sun protection products earn recommendation seals August 26, 2016 By Lisette Hilton CeraVe AM Facial Moisturizing Lotion SPF 30 and CeraVe Sunscreen SPF 50 for Face (both by Valeant Pharmaceuticals) have been awarded Skin Cancer Foundation seals. Best practices for treating severe sun damage August 12, 2016 By Lisette Hilton The goal of treatment for severely sun-damaged patients’ lesions is field therapy, which not only treats what dermatologists see, but also subclinical disease. Vismodegib study confirms safety, efficacy for BCC August 09, 2016 By John Jesitus The largest-ever vismodegib study in advanced basal cell carcinoma, the STEVIE study, confirms pivotal study findings in a real-world setting, helping dermatologists to provide a complete palette of skin cancer treatments. New target could predict melanoma August 08, 2016 By Lisette Hilton New information could eventually help identify a high-risk population before they get cancer — even prevent skin cancer’s onset. First do no Mohs harm August 08, 2016 By Lisette Hilton An expert advises evaluating each patient’s surrounding circumstances when determining whether Mohs surgery is indicated. How to weigh benefit of Moh's July 15, 2016 By Lisette Hilton Mohs surgery experts advise when Mohs is and isn’t optimal skin cancer treatment. Improving accuracy in NMSC diagnosis July 14, 2016 By John Jesitus The trend toward smaller biopsies may compromise the accuracy of dermatopathologists' diagnoses.